BSPK Bespoke Extracts, Inc.

OTC Pharmaceutical Preparations NV CIK: 0001409197
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Bespoke Extracts is in severe financial distress with negative stockholders' equity of -$2.6M, indicating liabilities exceed assets by a significant margin. Despite 42.3% revenue growth, the company is deeply unprofitable with a -48.5% net margin, burning cash at an alarming rate (-$723.6K free cash flow) while maintaining minimal liquidity (0.11x current ratio). The combination of deteriorating financial position, negative equity, and unsustainable cash burn presents an extreme capital structure risk.

Strengths

  • + Revenue growth of 42.3% year-over-year demonstrates market traction
  • + Gross margin of 48.4% suggests underlying product economics are viable
  • + Some improvement in diluted EPS despite continued losses

Risks

  • ! Negative stockholders' equity of -$2.6M indicates insolvency risk and potential total loss for equity holders
  • ! Critically low liquidity ratios (0.11x current ratio, 0.07x quick ratio) with only $16.7K cash against $2.9M liabilities
  • ! Severe cash burn with -$123.6K operating cash flow and -$723.6K free cash flow unsustainable without immediate capital injection
  • ! Operating margin of -41.1% with $461.2K operating loss shows inability to scale profitably
  • ! High capex of $600K relative to $1.1M revenue suggests investment-phase company without path to profitability

Key Metrics to Watch

Financial Metrics

Revenue
1.1M
Net Income
-543.7K
EPS (Diluted)
$-0.05
Free Cash Flow
-723.6K
Total Assets
295.6K
Cash
16.7K

Profitability Ratios

Gross Margin 48.4%
Operating Margin -41.1%
Net Margin -48.5%
ROE N/A
ROA -184.0%
FCF Margin -64.5%

Balance Sheet & Liquidity

Current Ratio
0.11x
Quick Ratio
0.07x
Debt/Equity
N/A
Debt/Assets
978.1%
Interest Coverage
-36.39x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-21T14:10:10.962599 | Data as of: 2025-09-30 | Powered by Claude AI